UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Combating castration-resistant prostate cancer by co-targeting the epigenetic regulators EZH2 and HDAC

PLoS biology, 2023-04, Vol.21 (4), p.e3002038-e3002038

2023

Link zum Volltext

Verfügbarkeit prüfen

The NF1 Tumor Suppressor Critically Regulates TSC2 and mTOR

Proceedings of the National Academy of Sciences - PNAS, 2005-06, Vol.102 (24), p.8573-8578

2005

Link zum Volltext

Verfügbarkeit prüfen

Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer

The Journal of clinical investigation, 2023-08, Vol.133 (16), p.1-16

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract IA23: Developing therapies for Ras-driven cancers

Molecular cancer research, 2020-05, Vol.18 (5_Supplement), p.IA23-IA23

Cichowski, Karen

2020

Link zum Volltext

Verfügbarkeit prüfen

ErbB-3 Mediates Phosphoinositide 3-Kinase Activity in Gefitinib-Sensitive Non-Small Cell Lung Cancer Cell Lines

Proceedings of the National Academy of Sciences - PNAS, 2005-03, Vol.102 (10), p.3788-3793

2005

Link zum Volltext

Verfügbarkeit prüfen

Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence

Cell reports (Cambridge), 2017-12, Vol.21 (10), p.2796-2812

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract IA28: Using mouse models to develop therapies for Ras-driven cancers

Cancer research (Chicago, Ill.), 2018-05, Vol.78 (10_Supplement), p.IA28-IA28

Cichowski, Karen

2018

Link zum Volltext

Verfügbarkeit prüfen

Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023)

Sarcoma, 2020, Vol.2020, p.5784876-8

2020

Link zum Volltext

Verfügbarkeit prüfen

Imaging Mass Spectrometry Reveals Tumor Metabolic Heterogeneity

iScience, 2020-08, Vol.23 (8), p.101355-101355, Article 101355

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract IA02: Developing therapies for Ras-driven cancers

Molecular cancer research, 2014-12, Vol.12 (12_Supplement), p.IA02-IA02

Cichowski, Karen

2014

Link zum Volltext

Verfügbarkeit prüfen

Tissue-specificity in cancer: The rule, not the exception

Science (American Association for the Advancement of Science), 2019-03, Vol.363 (6432), p.1150-1151

2019

Link zum Volltext

Verfügbarkeit prüfen

An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer

Advances in biological regulation, 2014-05, Vol.55, p.1-14

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract PL04-01: Developing therapies for Ras driven cancers

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.PL04-01-PL04-01

Cichowski, Karen

2013

Link zum Volltext

Verfügbarkeit prüfen

Loss of negative regulators amplifies RAS signaling

Nature genetics, 2015-05, Vol.47 (5), p.426-427

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-18-27: Developing a novel combination therapy using EZH2i for HER2+ breast cancer

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P1-P1-18-27

2020

Link zum Volltext

Verfügbarkeit prüfen

Loss of negative regulators amplifies RASAS signaling

Nature genetics, 2015-05, Vol.47 (5), p.426

2015

Link zum Volltext

Verfügbarkeit prüfen

Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is

Genes & development, 2018-09, Vol.32 (17-18), p.1188-1200

2018

Link zum Volltext

Verfügbarkeit prüfen

PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies

Nature (London), 2014-10, Vol.514 (7521), p.247-251

2014

Link zum Volltext

Verfügbarkeit prüfen

Targeting Cancer at the Intersection of Signaling and Epigenetics

Annual review of cancer biology, 2019-03, Vol.3 (1), p.365-384

2019

Link zum Volltext

Verfügbarkeit prüfen

Combating castration-resistant prostate cancer by co-targeting the epigenetic regulators EZH2 and HDAC

PLoS biology, 2023-04, Vol.21 (4)

2023

Link zum Volltext

Verfügbarkeit prüfen

NF1 Tumor Suppressor Gene Function: Narrowing the GAP

Cell, 2001-02, Vol.104 (4), p.593-604

2001

Link zum Volltext

Verfügbarkeit prüfen

Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance

Cancer cell, 2018-06, Vol.33 (6), p.985-1003.e7

2018

Link zum Volltext

Verfügbarkeit prüfen

Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy

Cell, 2015-02, Vol.160 (5), p.977-989

2015

Link zum Volltext

Verfügbarkeit prüfen

mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors

Cancer discovery, 2017-12, Vol.7 (12), p.1450-1463

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 95

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(85)
Mit Volltextzugriff
(83)

Publikationsform

Sprache

Englisch
(95)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Combating castration-resistant prostate cancer by co-targeting the epigenetic regulators EZH2 and HDAC

The NF1 Tumor Suppressor Critically Regulates TSC2 and mTOR

Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer

Abstract IA23: Developing therapies for Ras-driven cancers

ErbB-3 Mediates Phosphoinositide 3-Kinase Activity in Gefitinib-Sensitive Non-Small Cell Lung Cancer Cell Lines

Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence

Abstract IA28: Using mouse models to develop therapies for Ras-driven cancers

Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023)

Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)

Imaging Mass Spectrometry Reveals Tumor Metabolic Heterogeneity

Abstract IA02: Developing therapies for Ras-driven cancers

Tissue-specificity in cancer: The rule, not the exception

An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer

Abstract PL04-01: Developing therapies for Ras driven cancers

Loss of negative regulators amplifies RAS signaling

Abstract P1-18-27: Developing a novel combination therapy using EZH2i for HER2+ breast cancer

Loss of negative regulators amplifies RASAS signaling

Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is

PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies

Targeting Cancer at the Intersection of Signaling and Epigenetics

Combating castration-resistant prostate cancer by co-targeting the epigenetic regulators EZH2 and HDAC

NF1 Tumor Suppressor Gene Function: Narrowing the GAP

Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance

Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy

mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors

Suchergebnisse filtern